What is Inductive Bio?
Inductive Bio is at the forefront of pharmaceutical innovation, developing a sophisticated machine learning (ML) platform engineered to drastically expedite the compound optimization process. This critical phase in drug development, often a bottleneck, is addressed by Inductive's technology. The company builds extensive datasets and advanced ML models specifically designed to map the intricate drivers of small molecule Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET). By leveraging these capabilities, Inductive's platform empowers scientists to refine initial compounds into viable leads and development candidates with greater speed and an improved balance of ADMET properties, thereby streamlining the path to new therapeutics.
How much funding has Inductive Bio raised?
Inductive Bio has raised a total of $29.3M across 2 funding rounds:
Angel/Seed
$4.3M
Series A
$25M
Angel/Seed (2023): $4.3M with participation from Andreessen Horowitz, Lux Capital, Bessemer Venture Partners, and AlleyCorp companies
Series A (2025): $25M led by The Character Group, Lux Capital, Obvious Ventures, S32, Andreessen Horowitz, and Amino Collective
Key Investors in Inductive Bio
The Character Group
The Character Group PLC is a company specializing in the design, development, and distribution of toys, games, and giftware, sourcing products from overseas third parties to cater to a broad consumer market.
Lux Capital
Lux Capital Corporation is a multi-family office that connects enterprises to expertise, networks, and capital, with a focus on financial securities, real estate, energy, and social impact investments, aiming to drive advancements in various sectors.
Obvious Ventures
The Obvious Corp is a creative and design firm that transforms client ideas into marketing and communications materials, specializing in strategic design, copywriting, and illustration for a wide range of clients and formats.
What's next for Inductive Bio?
With the recent major strategic investment, Inductive Bio is poised for accelerated growth and further development of its ML-driven drug discovery platform. The substantial capital infusion, totaling $29.3M with the latest round contributing $25M, will likely be directed towards expanding research and development initiatives, enhancing the platform's capabilities, and potentially scaling its operations to meet the demands of the biopharmaceutical industry. This strategic financing suggests a focus on solidifying its market position and advancing its pipeline of optimized compounds, signaling a promising trajectory for the company in the competitive therapeutic development landscape.
See full Inductive Bio company page
